Targeting myelogenous leukemia stem cells: role of the circulation

Jane Liesveld*

Hematology/Oncology Division, University of Rochester, Rochester, NY, USA

Keywords: leukemia stem cells, antibody, signal transduction, vascular interactions, targeting

DEFINING THE LEUKEMIA STEM CELL AND ITS IMPORTANCE

Myeloid leukemias are a group of disorders arising in marrow and often involving blood which are characterized by overproduction of immature leukocytes or terminally differentiated cells as in chronic myelogenous leukemia (CML). In this review, we will focus on acute leukemias where impairment of differentiation is found. Most therapies available to treat acute myelogenous leukemia target leukemia blast cells which are in general a later progenitor/precursor cell no longer capable of self-renewal and multipotential differentiation. Only about 0.01% of normal marrow progenitor/precursor cell no longer capable of self-renewal and multipotential differentiation. This has led to the concept of stem cells, including leukemia stem cells (LSCs), to the vasculature. This poses unique problems in the targeting of LSCs since these cells are found circulating in the majority of leukemia cases at diagnosis and are usually not detectable during remission states. Because most cases of leukemia relapse, it is suggested that LSCs remain quiescent in the marrow until they eventually proliferate and circulate again. This indicates that effective targeting of LSCs must occur not only in peripheral circulation but in the micro-circulation of the marrow. Targeting such interactions may overcome cell adhesion-mediated treatment resistance, other multi-drug resistance mechanisms, and opportunities for clonal evolution in the marrow environment. Targeting selectins and integrins, signal transduction mediators, and chemokine/cytokine networks in the marrow micro-circulation may aid in abrogating leukemia-initiating stem cells which contribute to disease relapse. LSCs possess surface antigen profiles and signal transduction activation profiles which may allow differential targeting as compared with normal hematopoietic stem cells.

Unlike stem cells from solid tumors, the stem cells which initiate myelogenous leukemias arise in marrow, an organ with a unique circulation which allows ready access of leukemia cells, including leukemia stem cells (LSCs), to the vasculature. This poses unique problems in the targeting of LSCs since these cells are found circulating in the majority of leukemia cases at diagnosis and are usually not detectable during remission states. Because most cases of leukemia relapse, it is suggested that LSCs remain quiescent in the marrow until they eventually proliferate and circulate again. This indicates that effective targeting of LSCs must occur not only in peripheral circulation but in the micro-circulation of the marrow. Targeting such interactions may overcome cell adhesion-mediated treatment resistance, other multi-drug resistance mechanisms, and opportunities for clonal evolution in the marrow environment. Targeting selectins and integrins, signal transduction mediators, and chemokine/cytokine networks in the marrow micro-circulation may aid in abrogating leukemia-initiating stem cells which contribute to disease relapse. LSCs possess surface antigen profiles and signal transduction activation profiles which may allow differential targeting as compared with normal hematopoietic stem cells.

cell heterogeneity (Nguyen et al., 2012; Walter et al., 2012). Some leukemias may arise at the level of pluripotent CD34+ precursors, some may have an initial mutation in a pluripotent HSC with a collaborating mutation such as a core binding factor mutation occurring later, or some may arise at the level of a committed myeloid precursor as is the case in acute promyelocytic leukemia. The LSC may not always be a rare population of quiescent cells. The phenotype, frequency, and functional properties of these cells may also change during disease progression (Mather, 2012; Nguyen et al., 2012).

Bonnet and Dick (1997) found that only leukemic blasts with the immature cell-surface phenotype characterized by CD34 expression with lack of CD38 expression were capable of transferring AML to immunodeficient mice; severe combined immunodeficiency (SCID) mice. This seemed consistent with a cancer stem cell (CSC) hypothesis which suggests that tumors are maintained by a small population of stem cell-like cancer cells which have the capability for indefinite self-renewal (Lapidot et al., 1994). Subsequently, some leukemia-initiating cells (L-ICs) have been found in the CD34 negative marrow fractions (Tuveson et al., 2005). Also, LSCs have a hierarchy defined by length of repopulating potential in serial immune deficient mice transplantsations defined as short- and long-term potential (Sarry et al., 2011). Those with long-term potential are thought to be quiescent (outside of active cell cycle) and express high levels of the multi-drug resistance phenotype, MDR-1, indicating ability to efflux cytotoxic drugs (Krause and van Etten, 2007). There is also evidence that pathways involved in proliferation of primitive cells such as Hox, hedgehog, notch, and...
Wnt are all involved in the maintenance and proliferation of the LSC (reviewed in Krause and van Etten, 2007). While the CD34+CD38- cells are clonal as based on cytogenetics, fluorescence in situ hybridization (FISH), and reverse transcriptase polymerase chain reaction (RT-PCR) in some cases, normal CD34+CD38- cells are also capable of engrafting NOD/SCID mice and must be distinguished from their leukemic counterparts in the course of functional assays. If a multipotential CD34+CD38- stem cell is the cell of origin for acute leukemia, it is not known why the lymphoid phenotype is suppressed after transformation. Satoh and Ogata (2006) have postulated that myeloid HSCs with minimal lymphopoietic potential may be the site of transformation in AML and could be a target to eliminate the LSC in many cases.

The LSC is best defined functionally by its ability to recapitulate leukemia faithfully in immunocompromised mice. This requires not only homing and engraftment potential to the murine microenvironment but ability to express the phenotype of the original AML in terms of surface phenotype and of clonal markers such as chromosome translocations or deletions or of other abnormal molecular markers such as nucleophosmin-1, Flt3–ITD expression, or Ras mutations. Unfortunately, only about 50% of AML cases have clonal chromosome markers to allow easy distinction, but other aberrant leukemic cell phenotypes can sometimes allow the distinction of normal vs. leukemia human CD45 cells to be made by flow cytometry or by mutation analysis by PCR or sequencing. Detecting the presence of human CD45 cells is not sufficient as normal HSCs are also able to engraft immunodeficient mice, so documentation of the leukemic nature of the engrafting cells is required. In vivo L-IC and HSC assays are important to measure functional stem cell capability and to measure effectiveness of therapies against L-ICs as has been determined with a compound kinetin riboside which has potential therapeutic efficacy and preferential effects against LSCs as compared with normal HSCs (McDermott et al., 2012). Some AML do not engraft immune deficient mice, and it is thought that murine engraftment could represent proliferative potential of the leukemic cells or could simply reflect ability to interact with the murine microenvironment (Rusinero et al., 2011). Targeting LSCs is thought to be of importance since the burden of LSCs at diagnosis has prognostic significance. Patients whose blasts at diagnosis fail to engraft NOD/SCID mice at high cell doses have superior long-term survival (Pearce et al., 2006).

Knowing which “stem cell” to target therapeutically in AML is difficult, however, since relapse may occur in a founder clone, a recurring subclone, or in a novel stem cell clone (Walter et al., 2012). Not only do controversies exist about how to identify a LSC but also about whether such a stem cell must be eliminated in order to effectively treat the leukemia (Kelly et al., 2007; Majeti, 2011). The possibility that stem cell-like components of tumors may change phenotype rapidly and reversibly also makes study of these cells difficult (Mather, 2012). Because of the heterogeneity in the phenotype of LSCs, surface antigen phenotype is inadequate as a means of isolation. High expression of aldehyde dehydrogenase (ALDH) activity in conjunction with CD34 has been found to delineate an L-IC (Ran et al., 2012). The frequency of aldehyde bright cells in the marrow at time of initial diagnosis is an independent prognostic factor predicting overall survival (Ran et al., 2012). It has also been shown that in a majority of AML cases, two subsets with progenitor immunophenotype coexisted, and both have LSC activity and are hierarchically patterned (Gourden et al., 2011).

The stem cell model has clinical significance in AML is suggested by studies such as one which showed that the percentage of CD34+CD38- LSCs at the time of diagnosis correlated with the duration of relapse-free survival in 92 patients (van Rhemen et al., 2005). Those with >3.5% AML LSCs had a median relapse-free survival of 5.6 months vs. those with <3.5% who had a median relapse-free survival of 16 months. The presence of a CD34+CD38- ALDH intermediate population has been shown to correlate with minimal residual disease (MRD) and subsequent relapse and to be able to distinguish LSCs from normal stem cells which are aldehyde high expressors (Gerber et al., 2012). Overall, LSC frequency is thought to be an important component of MRD (Buccisano et al., 2012).

ASSAYING THE LSC

The LSC can be assayed by flow cytometry and immunophenotyping, but given the vagaries and lack of standardization of this technique, it is most accurately assayed by its ability to engraft immune deficient mice, although as noted above, there are both quantitative and qualitative problems with those assays (Mather, 2012). The L-IC is able to recapitulate the phenotype of the original leukemia when transplanted into NOD/SCID mice and then to be secondarily transplanted to another sublethally irradiated mouse. The NOD/SCID xenograft has no B or T cells, and leukemia engraftment is often quite low and requires transplantation of thousands of cells. In the NOD/SCID/IL-2Rγc−− (NSG) species, NK cells are also deficient and as few as 100 cells will transplant the leukemia (Ishikawa et al., 2005). ALDH has been utilized as a marker of LSCs, and in vitro long-term culture assays have been reported to identify an L-IC (Sutherland et al., 2001).

Initially, it was thought that the LSC resided in the CD34+CD38- compartment, but many anti-CD38 antibodies, including those utilized in the original isolation of LSCs inhibit engraftment of CD34+CD38- leukemia cells through an Fc-dependent mechanism (Taussig et al., 2008). Blockade of Fc receptors can result in engraftment of CD38+ AML cells, suggesting that CD38+ fractions may contain LSCs (Taussig et al., 2008). Also, in some AML cases with nucleophosmin mutation, the L-ICs reside in the CD34 negative fraction (Taussig et al., 2010). Table 1 illustrates some of the characteristics of AML stem cells as contrasted with normal HSCs.

MEANS TO TARGET LSCs

TARGETING CELL-SURFACE MOLECULES ON LSCs

One means of isolating and potentially targeting LSCs would be to target cell-surface molecules on the cell surface which are selectively or differentially expressed relative to normal tissue, in this case the normal HSC. Such antibodies could be expressed on differentiated normal cells but not on normal HSCs. LSCs lack Thy-1 (CD90) and c-kit (CD117), both found on normal HSCs, but they possess CD123, CD33, and C-type lectin-like molecule-1 (CLL-1).
Table 1 | Sample characteristics of leukemia vs. normal stem cells.

|                  | LSC                  | HSC                  |
|------------------|----------------------|----------------------|
| Frequency        | Usually rare          | Rare                 |
| Cell cycle status| Quiescent            | Quiescent            |
| MDR-1 expression | +                    | +                    |
| CD34 expression  | +                    | +                    |
| CD138 expression | Sometimes            | –                    |
| HLA-DR expression| –                    | –                    |
| CD71 expression  | –                    | –                    |
| CD33 expression  | – (Usually)          | –                    |
| CD90 expression  | +                    | +                    |
| CD123 expression | +                    | (Usually)            |
| Aldehyde dehydrogenase expression | + But intermediate | (Bright) |

LSC: leukemia stem cell; HSC: hematopoietic stem cell; MDR: multidrug resistance.

CD36, CD45, CD32, and CD25 have been shown to be preferentially expressed on AML stem cells as compared with normal HSCs (reviewed in Majeti et al., 2009). CD90 is expressed by normal but not AML stem cells (Baum et al., 1992). LSCs do not express human leukocyte antigen (HLA)-DR or CD71 (Blair et al., 1998). Many of these antigens are expressed on the cell surface, allowing stem cell targeting throughout the circulation without specific delivery requirements.

**ANTIGENS USED IN TARGETING AML LSCs**

**CD33**

CD33 is a sialylated protein expressed on normal cells with myelomonocytic differentiation, AML blasts, and some LSC populations. Numerous antibodies to CD33 have been developed for clinical use, including gemtuzumab ozogamicin, a recombinant humanized anti-CD33 conjugated with calicheamicin (Hamann et al., 2007). This conjugate induced remission in relapsed AML, most cases being CD33+, but it also had some activity in CD33- cases probably due in large part to the calicheamicin effects (Jawad et al., 2010; Pollard et al., 2012). It was also able to eliminate promyelocytes in cases of acute promyelocytic leukemia. While not studied directly, it was thought to differentially kill leukemia cells and possibly LSCs, but prolonged cytopenias also suggested in some cases that it was expressed on normal HSCs as well (Walter et al., 2012). Gemtuzumab ozogamicin (anti-CD33 conjugated with calicheamicin) was approved for the treatment of relapsed AML in elderly patients. Because CD33 is also expressed on endothelial cells of certain vascular beds, toxicities such as sinusoidal obstructive syndrome of liver occurred in some cases (McDonald, 2002), leading to eventual voluntary withdrawal of this conjugated antibody from the market. It is still being utilized in clinical trial settings, however, so future studies may be able to discern its effects on LSCs in states of MRD and other therapeutic settings in leukemia (Castaigne et al., 2012). Other antibody conjugates are also under development (Walter et al., 2012).

CD33 is a relatively hard molecule to target due to relatively low antigen expression (about 104 CD33 molecules/cell) and slow conjugate internalization (Walter et al., 2012). In CML, it has been found (Hermann et al., 2012b) that CD34+CD38−CD123+ cells expressed significantly higher levels of CD33 compared to normal CD34+CD38− stem cells. Levels of CD33 mRNA were also higher. Gemtuzumab ozogamicin inhibited these in long-term culture initiating cell assays, but no mention was made of inhibition of engraftment in NOD/SCID mice, however.

**CD123**

CD123 is the high-affinity interleukin-3 receptor alpha chain. While it is differentially expressed on leukemia vs. normal stem cells (Jordan et al., 2000), cord blood may express CD123 positive progenitors. CD123 has been targeted for clinical use with a diphtheria toxin–IL-3 fusion protein (Kuo et al., 2009) and numerous additional means to target CD123 have been developed. Jin et al. (2009) reported on a monoclonal antibody, 7G3 which targets CD123. It was able to reduce AML-LSC engraftment and improve murine survival in models of pre-established leukemia where the antibody showed reduced AML burden in the marrow and periphery as well as impaired secondary transplantation after 7G3 exposure, indicating that LSCs had been inhibited. Stem et al. (2009) used single chain Fv antibody fragments specific for CD123 designed to specifically target LSCs. This binding created two cell death inducing molecules; one being immunotoxic through truncation with a pseudomonas exotoxin and the other targeted to the low-affinity Fcy receptor III (CD16). This construct was able to generate potent lysis of MOLM-143, and SKNO-1 cells in ADCC reactions. None of the CD123 targeted agents have had significant clinical development to date.

**C-type lectin-like molecule 1**

This molecule has been found to be expressed on CD34+CD38− AML-LSCs. Its expression tracked with clinical remission or relapse. It was not found on CD34+CD38− cells from normal marrow or on cells regenerating post-chemotherapy (van Rhenen et al., 2007). Zhang et al. (2011) have developed nanoparticles covalently decorated with CLL-1 targeting peptides. These are loaded with daunorubicin which is then internalized to LSCs but not to normal HSCs. Other antibody means of targeting CLL-1 are also under development (Zha et al., 2010).

**CD96**

CD96 is a member of the immune globulin superfamily. It is normally found on T-lymphocytes. It is thought to be LSC-specific as it is found on most CD34+CD38− AML cells whereas it is only expressed weakly in the normal counterparts (Hosen et al., 2007). When leukemic cells were separated into CD96 positive and negative cells, only positive cells engrafted Rag-deficient mice, suggesting that this may be an LSC-specific therapeutic target.

**Anti-PR1/HLA-A2 T-cell receptor**

Antibodies against PR1 induce complement-dependent cytotoxicity against AML progenitor cells. PR1 is a HLA-A2 restricted leukemia-associated peptide from proteinase 3 (P3) and neutrophil elastase (NE) recognized by anti-PR1-specific cytotoxic
T lymphocytes which can contribute to cytotoxic remission of AML. These cells cause specific lysis of AML, including LSCs (Sergova et al., 2011).

CD44

The CD44-6v isoform is differentially expressed by AML progenitor cells. An activating CD34-specific antibody was able to eradicate AML but not normal cord blood and normal adult marrow engraftment in NOG/SCID mice (Jin et al., 2006). In vivo, the effect of this antibody, 1H9 was limited to situations with a lower burden of disease (Jin et al., 2006).

CD32

This antigen has been reported by Saito et al. (2010) to be differentially expressed on the AML stem cell. It recognizes the FcRβa low-affinity receptor and so is expressed on monocytes and other effectors of ADCC as well.

CD47

Saito et al. (2010) also described this on the AML stem cell. Either CD32 or CD25 or both were expressed in 32/61 (53%) of patients in AML LSCs which were able to initiate AML and were cell-cycle quiescent and chemotherapy resistant in vivo.

CD47 is a ligand to SIRP alpha (signal regulatory protein-alpha). Its expression sends a "don't eat me" message to phagocytic cells. Blocking antibodies to CD47 enabled phagocytosis of human AML LSCs but not normal LSCs (Jaiswal et al., 2009). This antibody has been found effective in a treatment model where NSG mice were transplanted with LSCs. After 8–12 weeks the mice were treated with control IgG or blocking antibodies to CD47. The antibodies to CD47 resulted in rapid clearance of AML in blood and also of marrow LSCs. There was absence of leukemia in secondary recipients (Majeti et al., 2009). CD47 is expressed on many tissues, and it may be more effective with chemotherapy or with mobilizing agents to facilitate phagocytosis in the peripheral circulation (Majeti et al., 2009).

SUMMARY OF ANTIBODY TARGETING

While antibodies have been developed to target differentially expressed surface markers on AML vs. normal cells, none of these have had significant impact on disease outcomes to date. In part, this may be due to lack of complete specificity, inadequate targeting, toxicities due to non-specificity, antigen modulation, and subsequent resistance, or other as yet undiscovered mechanisms. Despite its removal from the market in the United States, its expression sends a "don't eat me" message to phagocytic cells. Blocking antibodies to CD47 enabled phagocytosis of human AML LSCs but not normal LSCs (Jaiswal et al., 2009). This antibody has been found effective in a treatment model where NSG mice were transplanted with LSCs. After 8–12 weeks the mice were treated with control IgG or blocking antibodies to CD47. The antibodies to CD47 resulted in rapid clearance of AML in blood and also of marrow LSCs. There was absence of leukemia in secondary recipients (Majeti et al., 2009). CD47 is expressed on many tissues, and it may be more effective with chemotherapy or with mobilizing agents to facilitate phagocytosis in the peripheral circulation (Majeti et al., 2009).

TARGETING SIGNALING PATHWAYS IN LSCs WITH SMALL MOLECULE INHIBITORS

One approach to eliminating the LSC would be to target pathways regulating stem cell self-renewal, particularly if these are differentially expressed in LSCs vs. HSCs (Rasheed et al., 2011). For example, inhibitors of Wnt have been examined in CML (Baghdadi et al., 2012) and notch inhibitors have been examined in AML, but these are also toxic to normal HSCs in some cases, indicating a need to find selective inhibitors or relatively selective inhibitors for LSCs (Gurman and Jordan, 2004; Mikkola et al., 2010). Heat shock protein inhibitors have been found to be inhibitory to AML progenitor cells, but whether those represent true stem cells is uncertain (Hermann et al., 2012a).

PI3K/AKT/mTOR PATHWAY

The PI3K/AKT/mTOR pathway is activated in the majority of AML cases, but the effects of inhibiting this pathway on LSC frequency have not been described in detail (Mikkola et al., 2010). In mice, when PTEN, normally a suppressor of the PI3K/AKT/mTOR pathway is depleted, normal HSCs are depleted, but L-ICs are expanded (Lee et al., 2010). The mTOR inhibitor, rapamycin, blocks this. The depletion of Pten-deficient HSCs was not caused by oxidative stress (Peng et al., 2010). Altman et al. (2011) have found that dual targeting of mTORC1 and mTORC2 results in potent suppressive effects on primitive leukemic progenitors from AML patients. Inhibition of the mTOR catalytic site with OSI-027, a dual mTORC1/mTORC2 inhibitor, resulted in suppression of mTORC2 and mTORC1 complexes and elicited a much more potent anti-leukemic response than selective mTORC1 targeting with rapamycin. Whether these inhibitors act at a true stem cell level remains unclear.

NF-κB pathway

NF-κB has been found to be active in most AML stem cells but not in normal lineage-negative progenitors (Jordan et al., 2006). The proteasome inhibitor, MG-132, inhibited NF-κB activation through stabilization of its cellular inhibitor, IκB and was able to induce apoptosis in CD34+CD38−AML cells while sparing normal progenitors. Since that report, other inhibitors of NF-κB such as bortezomib or specific inhibitors of IκB kinase which phosphorylate and inactivate IκB have been developed and have been reported to be inhibitory to AML progenitor cells (Frelin et al., 2005). The drug parthenolide has IκB-loc inhibitory activity and is able to induce apoptosis in AML cells coincident with NF-κB inhibition, p53 activation, and induction of reactive oxygen species (Neelakantan et al., 2009).

Tyrrosine kinase inhibitors

These have been utilized primarily to target bcr/abl, the driving mechanism in CML. While most bcr/abl inhibitors such as imatinib mesylate, nilotinib, and dasatinib eradicate most CML cells, they are ineffective against a reservoir of quiescent LSCs (Baghdadi et al., 2012). Inhibition of the Wnt/beta-catenin, hedgehog, and histone deacetylases has been shown to have potential to inhibit the CML stem cell.
Hedgehog/smoothed pathway
Hedgehog signaling is essential for maintenance of CSCs (Zhao et al., 2009). Loss of smoothed, an essential component of the Hedgehog pathway, impairs HSC renewal and decreases induction of CML by bcr/abl. Inhibition of hedgehog by cycloamine inhibited the propagation of CML. In contrast, hedgehog signaling is not required for adult murine HSC function and hematopoesis (Su et al., 2012). Its role in an AML LSC is not well worked out yet, but inhibitors of the Wnt and Shh signaling pathway cause less apoptosis in normal vs. leukemic HSCs (Hofmann et al., 2009).

Oxidative stress pathways
While states of low oxidative stress are thought to aid in maintenance of stem cell quiescence, CSCs may be susceptible to agents which induce oxidative stress. In fact, excessive production of ROS or a deficiency in antioxidant pathways has been noted in acute leukemias (Holm et al., 2011). This has not been studied systematically as a means of differential LSC targeting.

TARGETING VASCULAR INTERACTIONS
Since LSCs as well as their blast progeny can be isolated from the vasculature in which they circulate, it is likely that exploitation of LSC-vascular interactions would have greater impact on targeting these stem cells than would be the case in other cancers where the stem cells do not routinely circulate except at times of active metastasizing. Furthermore, the LSC arises in the marrow microenvironment, an organ that is very vascular, again suggesting a potential role for targeting leukemia/vascular interactions. In the marrow, LSCs interact with cells, matrix, and soluble factors in the microenvironmental niche (Konopleva and Jordan, 2011). In mice, the microenvironmental niche has been characterized as vascular and osteoblastic, but whether such distinct niches exist in human marrow is uncertain. When leukemia cells enter the blood, they must traverse the endothelial cells lining the marrow sinusoids which comprise the vascular niche, and when they return to the marrow, they are engaged by selectins for rolling on the endothelial layer after which they attach via integrins or other adhesins. Thereafter, they transmigrate the endothelial barrier before again lodging in the marrow niche.

Role of endothelial cells
As noted above, when LSCs and other AML cells home to marrow or egress marrow to the peripheral circulation, they must traverse an endothelial monolayer. These form an intact lining of marrow sinusoidal vessels. The homing process involves rolling on selectin surfaces, engaging integrin or other adhesion receptors, transmigrating the endothelial layer, and lodging in the marrow hematopoietic niche. Chemotherapy resistant AML stem cells are thought to engraft with the marrow endosteal region (Ishikawa et al., 2004). Stem cell interactions with the niche can therefore theoretically be disrupted at each of these steps with possible impact on survival, proliferation, and function. Sipkins et al. (2005), using intravital microscopy showed that NALM-6, an ALL cell line, engrafted in microvascular domains in the marrow. Colmone et al. (2008) demonstrated that the NALM-6 cells actively disrupted normal vascular niches for transplanted human CD34+ cells and caused normal CD34+ cells to leave their niches and to engraft in alternative niches. Targeting the supportive function of the vascular niche in marrow and circulation may therefore have inhibitory activity against LSCs. Whether this will have a differential effect as compared with normal stem cells remains uncertain.

Targeting vascular endothelial growth factor (VEGF) and its receptor, VEGFR2 (KDR) may inhibit both AML cells and endothelial cell proliferation as both possess these receptors (Ziegler et al., 1999). Marrow vascularity is increased in AML, and targeting this vasculature may decrease AML proliferation. The role of specific angiopeptins such as basic fibroblast growth factor or transforming growth factor-beta has not been examined as related to AML stem cell survival, but this might also represent pathways which might be targeted to decrease proliferation of AML cells (Volkman, 2001). It has also been demonstrated that leukemia cells secrete factors which can enhance endothelial cell proliferation which in turn can stimulate leukemia cell proliferation and survival (Veiga et al., 2006). Targeting endothelial cells via inhibition of the angiopeptin– Tie2 axis (Schliemann et al., 2007) or via combrestatins (Pett et al., 2008) might also inhibit leukemia cell proliferation, but specificity for LSCs has not been determined.

CXCL12 and CXCR4
The CXCL12–CXCR4 chemokine–chemokine receptor axis is involved in AML stem cell interaction with the marrow as is also the case with normal HSCs. CXCR4 is expressed on primary leukemia cells, and high expression is a negative prognostic factor (Rombouts et al., 2004). Treatment with the CXCR4 antagonist,plerixafor, has been found to increase sensitivity of Flt-3 mutated AML cells to the FLT3 inhibitor, sorafenib and to induce the mobilization of AML cells into the peripheral blood (Zeng et al., 2009). It is uncertain whether there is preferential mobilization of LSCs vs. normal progenitors and bulk AML cells.

Anti-VLA-4 and anti-VCAM
The integrin–integrin receptor pair of very late antigen-4 and vascular cell adhesion molecule-1 is involved in retention of AML cells in marrow. AML blasts with higher CD49d expression have a poorer prognosis (Matsumaga et al., 2003), but the function of very late-antigen-4 as measured by binding of soluble VCAM-1 may be associated with improved overall survival of patients (Becker et al., 2009). Interactions between VLA-4 and fibronectin or VCAM may modulate chemotaxis response. How this impacts AML stem cells remains uncertain. Targeting other integrin-linked pathways may also inhibit AML stem cells (Muranyi et al., 2010).

Role of CD44
CD44 is a glycoprotein which binds to hyaluronan, selectins, and osteopontin and has pleiotropic functions in organogenesis, cell homing, and migration (Krause et al., 2006). High levels of the molecule on AML cells are associated with higher relapse rates (Quere’ et al., 2011). The anti-CD44 antibody, H90 targets LSCs in human AML through niche disruption and with evidence of LSC targeting, and late-antigen-4 as measured by binding of soluble VCAM-1 may be associated with improved overall survival of patients (Becker et al., 2009). It has also been demonstrated that leukemia cells secrete factors which can enhance endothelial cell proliferation which in turn can stimulate leukemia cell proliferation and survival (Veiga et al., 2006). Targeting endothelial cells via inhibition of the angiopeptin– Tie2 axis (Schliemann et al., 2007) or via combrestatins (Pett et al., 2008) might also inhibit leukemia cell proliferation, but specificity for LSCs has not been determined.

www.frontiersin.org August 2012 | Volume 2 | Article 86 | 5
of NOD/SCID mice was markedly reduced probably due to interference with transport to the stem-cell-supportive niches. Since CD44 is ubiquitously expressed, it is not known if the differential effects on LSCs are due to alternative splicing or other reasons.

Role of hypoxia

The marrow microenvironment in AML is relatively hypoxic (Fiegli et al., 2009). Under normoxic conditions, it has been found (Wang et al., 2011) that HIF-1α signaling was selectively activated in the stem cells of murine lymphoma and human AML. HIF-1α shRNA and HIF-1α inhibitors abrogated the colony-forming unit (CFU activity) of human CSCs. The inhibitor echinomycin eradicated serially transplantable human AML cells in xenogeneic models by preferential elimination of leukemic-cancer-specific stem cells. The increased HIF-1 activity in cancer stem cells was seen in both hypoxic and normoxic states. Rakinicin A is another compound which may target a hypoxic microenvironment (Yamazaki et al., 2007).

Role of selectins

Leukemic stem cells express sialylated carbohydrate ligands on their surfaces that adhere to selectin proteins found on endothelial cells. In marrow vascular beds, these selectins are constitutively expressed. Immobilized selectin protein can be utilized as a targeting mechanism for cells under flow and can capture some LSCs. Mitchell et al. (2012) have utilized targeted liposomal doxorubicin (L-DXR) functionalized with recombiant human E-selectin and polyethylene glycol. Normal leukocytes exposed to these molecules microtubules have been found to enrich for some hematopoietic progenitors from marrow through differential rolling (Narasipura et al., 2008), and this observation may allow delivery of cytotoxic agents targeting this selectin. P-selectin coated microparticles have been found to capture some LSCs which are thought to require elimination if AML therapies are successful. These selectins may also allow delivery of cytotoxic agents targeting LSCs. The increased HIF-1 activity in cancer stem cells was seen in both hypoxic and normoxic states. Rakinicin A is another compound which may target a hypoxic microenvironment (Yamazaki et al., 2007).

Role of cell cycle

Chemotherapy agents used to treat leukemia kill cells that are in active cell cycle but spare LSCs which are in a quiescent state in the marrow endosteal niche. Like normal stem cells, LSCs are predominately in a quiescent state which allows avoidance of stem cell exhaustion and minimization of risk of oncogenic events. Those LSCs located more centrally in the marrow cavity have a higher likelihood of being in active cell cycle (Doan and Chute, 2012). Attempts have been made to use agents such as granulocyte colony stimulating factor to cause LSCs to cycle, disrupting them from their vascular niche and increasing their sensitivity to agents such as cytarabine (Mikkola et al., 2010). Such efforts have not had great therapeutic impacts, however (Pabst et al., 2012).

SUMMARY

The LSC, like its normal stem cell counterpart, lodges in marrow niches and occasionally circulates in the blood. Ideally, a therapeutic strategy that targets LSCs must spare self-renewing normal HSCs so as to protect ongoing hematopoiesis. The comparison of LSCs vs. HSCs functionally is crucial to identifying unique properties of the LSC which can be targeted. These will include surface antigen phenotyping (Amadori and Stasi, 2006), comparison of signal transduction pathway activation, response to reactive oxygen species and stress protein responses at baseline and in response to chemotherapeutic agents. Also, understanding differences in interactions with vasculature peripherally and in marrow may allow for differential targeting of LSCs (Doan and Chute, 2012). The ideal target will thus be expressed on a large fraction of LSCs, be stable through treatment types and disease stages, be present on cell-cycle quiescent AML-initiating cells residing within the endosteal niche, and be non-toxic to normal HSCs. Determining the clinical effectiveness of agents which target stem cells and proving that this is clinically relevant is hard to achieve even in AML, but novel agents and appropriate biomarkers may allow application of these strategies for the future (Rashheed et al., 2011). LSCs are heterogeneous, grow in subclones which have some degree of genetic instability, and evolve with time. Many LSC-derived subclones may be undetectable at diagnosis, but after therapy, they may become the dominant clone with relapsing disease (Nguyen et al., 2012). Both rare cancer stem cells and dominant clones will need to be eliminated for successful disease control (Adams and Strasser, 2008). Understanding the interaction between LSCs and microenvironmental components may also elucidate means to target these rare cells (Klyuchnikov and Kroger, 2009). Due to the heterogeneity of the LSC and the similarities between HSCs and LSCs, many challenges remain in effective targeting of these rare cells which are thought to require elimination if AML therapies are to have long-term success (Krause and van Etten, 2007).

REFERENCES

Adams, J. M., and Strasser, A. (2008). In tumor growths sustained by rare cancer stem cells or dominant clones? Cancer Res. 68, 4010–4021.

Altman, J. K., Sanzana, A., Kaur, S., Glazer, H., Krezciokpyh, B., Reddy, A. J., Russo, S., Rier, S., and Pfitzmann, L. C. (2011). Dual mTORC2/mTORC1 targeting results in potent suppressive effects on acute myeloid leukemia (AML) progenitors. Clin Cancer Res. 17, 4378–4386.

Amadori, S., and Stasi, R. (2008). Monoclonal antibodies and immunotoxins in acute myeloid leukemia. Best Pract. Res. Clin. Haematol. 19, 715–756.

Braggink, T. A., Bronson, E., and Brown, H. S. (2011). Novel combination treatments targeting chronic myeloid leukemia stem cells. Curr. Lymphoma Myeloma Leuk. 12, 94–103.

Baum, C. M., Nüssmann, I. L., Tkachuk, A. S., Bucree, M., and Poult, R. (1992). Isolation of a candidate human hematopoietic stem-cell population. Proc. Natl Acad. Sci. U.S.A. 89, 2804–2808.

Becker, P. S., Kopecky, K. J., Wilks, A. W., Chera, S., Harlan, I. M., Wilm, C. L., Petersoid, S. H., Scriver, D. L., Papayannopoulou, T., and Appelbaum, F. R. (2009). Very late antigen-4 function of myeloblasts with improved survival for patients with acute myeloid leukemia. Blood 113, 866–874.

Blair, A., Hogge, D. E., and Buecher, P. S., Kopecky, K. J., Wilks, A. W., Chera, S., Harlan, I. M., Wilm, C. L., Petersoid, S. H., Scriver, D. L., Papayannopoulou, T., and Appelbaum, F. R. (2009). Very late antigen-4 function of myeloblasts with improved survival for patients with acute myeloid leukemia. Blood 113, 866–874.

Bucigross, F., Mauzillo, L., Del Principe, M. L., Del Pozo, G., Scorsoba, G., Lo-Coco, F., Arone, W., Amadori, S., and Venditti, A. (2012). Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 119, 332–341.

Becker, P. S., Kopecky, K. J., Wilks, A. W., Chera, S., Harlan, I. M., Wilm, C. L., Petersoid, S. H., Scriver, D. L., Papayannopoulou, T., and Appelbaum, F. R. (2009). Very late antigen-4 function of myeloblasts with improved survival for patients with acute myeloid leukemia. Blood 113, 866–874.

Bucigross, F., Mauzillo, L., Del Principe, M. L., Del Pozo, G., Scorsoba, G., Lo-Coco, F., Arone, W., Amadori, S., and Venditti, A. (2012). Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood 119, 332–341.
Goarden, N., Marchi, E., Atzberger, Folkman, J. (2001). Angiogenesis.

Doan, P. L., and Chute, J. P. (2012).

Colmone, A., Amorim, M., Pontier, A. L., Wang, S., Jablonski, E., and Sipkens, D. A. (2008). Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 322, 1601–1605.

Vascular niche: home for normal and malignant hematopoietic stem cells. Leukemia 26, 54–62.

Fugle, M., Sammalla, L., Cito-Doyt, K., Birk, I. K., Muyan, Z., and Andresson, M. (2009). CD44 is expressed and interacts with angiogenesis in acute myeloid leukemia are dependent on oxygen partial pressures. Blood 113, 1504–1512.

Fellmann, C. (2013). Angiogenesis-dependent disease. Senesc. Oncol. 6, 506–542.

Fredericks, H., Imbert, V., Grussmann, E., Peryton, A. C., Roucher, N., Philip, R., Dagera, C., Servet, A., Hummel, M., Berard, D., Descamps, M., Servet, N., and Peryton, J. F. (2009). Targeting NF-kappaB activation via pharmacologic inhibition of IKK2-induced apoptosis of human acute myeloid leukemia cells. Blood 105, 884–891.

Garbiso, Smith, B. D., Nyborg, Z., Zhang, H., Valva, M. S., Mose, B., Beduino, G., Collister, M. R., Peruzzi, B., Lewis, M. J., Griffin, C. A., Shankar, S. I., Bowerman, M. J., Karp, J. E., and Jones, R. J. (2012). A clonally relevant population of leukemic CD34(+CD38(-)) stem cells in acute myeloid leukemia. Blood 119, 5781–5787.

Guarino, N. Marchi, A., Auberger, A., Qadri, L., Schau, A., Sontsi, S., Wolf, E., Mudal, A., Allard, K. A., Root, R., Schindhelm, S., Gilks, A., Knapp, S., Bjerklie, K., Begum, S., Rose, S., Goldie, N., Grifflit, M., Sundan, S., Stengbom, A., Cavagneri, J., Hunner, H., Bosson, D., Ekelik, S., Robinson, L., Price, A., Giglio, E., Perry, V., Burnett, A., Craddock, C., Enver, T., Jacobson, S., Peverley, C., and Vyas, P. (2011). Coexistence of LEMP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19, 138–152.

Gutmann, M. L., and Jordan, C. T. (2004). Considerations for targeting malignant stem cells in leukemia. Cancer Cell 11, 97–104.

Hemmati, P. R., Hirman, L. M., Holland, I. B., Ciferri, C., Lelli, D., Holobon, R., Hallett, W., Tiso, H. H., Uppole, J.,ショット, D., Mountman, A., Flowers, D. A., and Bernstein, I. 2002. Gene-specific targeting. Blood 93, 57–66.

Hemmati, H., Kranshage, M., Généry, Reineiter, S., Bucido, T., Willmann, M., Glatt, K. E., Hemm, G., Prior, S., Baim, E., Baim, E., Prior, S., E., S., and P., E. 2012. Concise review: targeting of acute myeloid leukemia. Blood 119, 3731–3737.

Hemmati, H., Généry-Reineiter, S., Généry, K. V., Blatt, K., Hernal, Hofsohner, S., Bajnok, J., Winger, M., Menzer, A., Heidenthal, G.-S., Strubel, B., Selton, E., Schwarzwald, L., Sper, W.-R., and Velten, P. (2012). The Hyp2 inhibition: SMAD-ZnPP and PEG-ZnPP stall major growth-inhibitory effects on CD34(+)CD38(−) and CD34(+)CD38(−) AML progenitor cells. Cell Cancer Drug Targets 12, 51–63.

Hemmati, H., Généry-Reineiter, S., Généry, K. V., Blatt, K., Hernal, Hofsohner, S., Bajnok, J., Winger, M., Menzer, A., Heidenthal, G.-S., Strubel, B., Selton, E., Schwarzwald, L., Sper, W.-R., and Velten, P. (2012). The Hyp2 inhibition: SMAD-ZnPP and PEG-ZnPP stall major growth-inhibitory effects on CD34(+)CD38(−) and CD34(+)CD38(−) AML progenitor cells. Cell Cancer Drug Targets 12, 51–63.

Hoffman, L., Sorette, E. H., Cullen, D. E., Mac, J., Morgan, K. L., Luo, H., Kharas, M. G., Miller, P. G., Gomis, M. G., Ohake, R., Amin, A. A., Gribble, G., Gould, L., de Saquage, F. J., McIlhannon, A. P., and Gililand, D. G. (2009). Hedgehog signaling is dispensable for adult hematopoietic disease. Proc. Natl. Acad. Sci. U.S.A. 106, 23959–23964.

Hoffman, L., Sorette, E. H., Cullen, D. E., Mac, J., Morgan, K. L., Luo, H., Kharas, M. G., Miller, P. G., Gomis, M. G., Ohake, R., Amin, A. A., Gribble, G., Gould, L., de Saquage, F. J., McIlhannon, A. P., and Gililand, D. G. (2009). Hedgehog signaling is dispensable for adult hematopoietic disease. Proc. Natl. Acad. Sci. U.S.A. 106, 23959–23964.

Hoffmann, L., Sorette, E. H., Cullen, D. E., Mac, J., Morgan, K. L., Luo, H., Kharas, M. G., Miller, P. G., Gomis, M. G., Ohake, R., Amin, A. A., Gribble, G., Gould, L., de Saquage, F. J., McIlhannon, A. P., and Gililand, D. G. (2009). Hedgehog signaling is dispensable for adult hematopoietic disease. Proc. Natl. Acad. Sci. U.S.A. 106, 23959–23964.

Hoffmann, A., Kuroda, M., Tanaka, S., Tani, H., Nakamura, R., Tanaka, T., Terumitsu, H., Sato, N., Fukata, M., Miyamoto, Y., Lyman, B., Ohshima, K., Uchida, N., Taniguchi, S., Ohara, O., Akashi, K., Harada, M., and Shults, L. D. (2004). Chemotherapy-resistant human AML stem cells home to and engraft within the bone marrow endosteal region. Nat. Biotechnol. 22, 135–142.

Jawad, S., Jameson, C. H., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Trave, D., van Besouw, N., and Weissman, I. L. (2009). CD47 is upregulated on circulating hematopoietic stem cells and leukemic cells to avoid phagocytosis. Cell 139, 271–285.

Jawad, S., Seidlerou, C., Meng, U., Grundy, M., Bassal, N. H., and Pallis, M. (2010). Analysis of factors that affect in vivo chemosensitivity of leukemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia. Leukemia 24, 74–80.

Jin, L., Ho, K., Liu, Z., Smalla, J., and Dick, J. E. (2006). Targeting of CD34+ enriches human acute myeloid leukemia stem cells. Nat. Med. 12, 1137–1143.

Jin, L., Lee, E., Ruan, D., Hsu, S., Bushfield, S. J., Popping, A. G., Wilkinson, L., Gaffney, M. A., Thomas, D., Barry, E. F., Boyd, A., Geraghty, D. P., Vinz, G., Loper, A. F., Dick, J. E., and Lock, R. B. (2009). Monoclonal antibody-mediated targeting of CD34(+)CD38(−) leukemic stem cells. Stem Cell 37, 31–42.

Jordan, C. T., Guzman, M. L., and Noble, M. (2006). Cancer stem cells. Nat. Rev. Cancer 7, 575–587.

Jordan, C. T., Truchelut, D., Sabatier, S. I., Guzman, M. L., Howard, D. S., Petegore, A. L., Meyerson, T., Roni, R., Griva, B., Reiterer, D. A., Loper, S. M., and Phillips, G. L. (2006). The interleukin-3 receptor alpha chain, eliminates human acute myeloid leukemia stem cells. Stem Cell 34, 31–42.

Krause, D. S., and Van Etten, R. A. (2007). Right on target: eradicating leukemia stem cells. Trends Mol. Med. 13, 470–481.

Krause, D. S., and Van Etten, R. A. (2007). Right on target: eradicating leukemia stem cells. Trends Mol. Med. 13, 470–481.

Krause, D. S., and Van Etten, R. A. (2007). Right on target: eradicating leukemia stem cells. Trends Mol. Med. 13, 470–481.
Targeting leukemia stem cells

Neelakantan, S., Nasim, S., Guzman, N., Narasipura, S. D., Wojciechowski, J., Mitchell, M. J., Chen, C. S., Ponmudi, Mikkola, H. K., Radu, C. G., and Witte, McDermott, S. P., Eppert, K., Notta, L., Liesveld Targeting leukemia stem cells

V ekmans, M. C., Biemond, B., Son-W., Schouten, H. C., Graux, C., A. (2009). Targeting the leukemic

Wrana, J., Minden, M. D., and Dick, J. Study Group (AMLSG); the Swiss Hemato-Oncology Cooperative

Jacky, E., Bargetzi, M., Maertens, Eaves, C. J. (2012). Cancer stem cells: Bioorg. Med. Chem. Lett ery of the NF-

Novo mAb against leukemia stem cells but spares normal hematopoietic stem and progenitor cells through beta-

Vanherle, A., Feller, N., Kelder, A., Woestra, A. H., Rombouts, E., Zwagman, S., van der Pal, M. A., Wainfer, Q., Ossenkoppele, G. J., and Schuur, E. J. Clinical trials in leukemia stem cells.

van Rhenen, A., van Dongen, G. A., Kelder, A., Rombouts, E., Feller, N., Moskawa, B., Stoecker, I., van der Pal, M. A., Wainfer, Q., Ossenkoppele, G. J., and Schuur, E. J. (2005). High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin. Cancer Res. 11, 6520–6527.

van Rhenen, A., van Dongen, G. A., Kelder, A., Rombouts, E., Feller, N., Moskawa, B., Stoecker, I., van der Pal, M. A., Wainfer, Q., Ossenkoppele, G. J., and Schuur, E. J. (2005). High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin. Cancer Res. 11, 6520–6527.

van Rhenen, A., van Dongen, G. A., Kelder, A., Rombouts, E., Feller, N., Moskawa, B., Stoecker, I., van der Pal, M. A., Wainfer, Q., Ossenkoppele, G. J., and Schuur, E. J. (2005). High stem cell frequency in acute myeloid leukemia at diagnosis predicts high minimal residual disease and poor survival. Clin. Cancer Res. 11, 6520–6527.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.

review: emerging concepts in clinical targeting of cancer stem cells. Curr. Opin. Clin. Oncol. 21, 597–604.
Acute myeloid leukemia stem cell and CD33-targeted immunotherapy. Blood 119, 6198–6208.
Wang, Y., Lui, T., Malik, S. N., Zhong, P., and Liu, Y. (2011). Targeting HIF-1α eliminates cancer stem cells in hematological malignancies. Stem Cell 8, 399–411.
Younes, Y., Kamimoto, S., Ikeda, D., and Rakshit, A. (2007). A hypoxia-selective cytostatin. Biof. Pharm. Bull. 30, 261–265.
Zeng, Z., Sha, Y. X., Sanoaka, I. J., Wang, B. Y., Ling, X., Forero, O., Leon, M., Rubin J. B., Negrin, R. R., Estey, E. H., Knepler, S., Andreeff, M., and Konopleva, M. (2009). Targeting the leukemia microenvironment by CX3CR1 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 113, 6215–6224.
Zhang, H., Luo, J., Li, Y., Henderson, P. T., Wang, Y., Wachmann-Hüggi, S., Zhao, W., Lu, S. K., and Pan, C. (2011). Characterization of high-affinity peptides and their feasibility for use in nanotherapeutics targeting leukemia stem cells. Nanomedicine, doi: 10.1016/j.nano.2011.12.004 (Epub ahead of print).
Zhao, C., Chen, A., Jamesson, C. H., Foroshesh, M., Abrahamsson, A., Burn, J., Koon, H. Y., Kim, J., Chua, J. F., Kim, D., Münchhof, M., VanAndel, T., Reisfeld, R. A., and Reya, T. (2009). Hedgehog signaling is essential for maintenance of cancer stem cells in myeloid leukemia. Nature 458, 776–779.
Zhao, X., Singh, S., Pedrón, C., Zhao, J., Liu, E. D., Abu, A., and Kerver, W. (2010). Targeting C-type lectin-like molecule-1 from antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica 95, 71–78.
Zagler, R. L., Väärä, M., Porada, G. A., De Maria, R., Muller, R., Musella, B., Gabbanelli, M., Cassella, I., Poloni, E., Bock, T., Zenni, E. D., and Pochle, C. (1999). KDR receptor: a key marker defining hematopoietic stem cells. Science 285, 1553–1558.
Conflict of Interest Statement: The author declares that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Received: 11 June 2012; paper pending published: 22 June 2012; accepted: 16 July 2012; published online: 02 August 2012.